|
Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective. |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche; Tesaro |
Consulting or Advisory Role - Roche |
Speakers' Bureau - Novartis; Roche |
Research Funding - Janssen |
|
|
Employment - Bristol-Myers Squibb |
Leadership - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Bristol-Myers Squibb |